Platelet aggregability, thromboxane A2 and malonaldehyde formation following administration of aspirin to man.
D000328:Adult; D001095:Arachidonic Acids / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D001792:Blood Platelets / Q000378:metabolism; D003327:Coronary Disease / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008314:Malonates / Q000096:biosynthesis*; D008315:Malondialdehyde / Q000096:biosynthesis*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D010974:Platelet Aggregation / Q000187:drug effects*; D013928:Thromboxane A2 / Q000096:biosynthesis*; D013931:Thromboxanes / Q000096:biosynthesis*
D001095:Arachidonic Acids; D008314:Malonates; D013931:Thromboxanes; D008315:Malondialdehyde; D013928:Thromboxane A2; D001241:Aspirin